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Abstract
Background: The contrast agent (CA) dose for abdominal computed tomography (CT) is typically based on patient
total body weight (TBW), ignoring adipose tissue distribution. We report on our experience of dosing according to
the lean body weight (LBW).
Methods: After Ethics Committee approval, we retrospectively screened 219 consecutive patients, 18 being
excluded for not matching the inclusion criteria. Thus, 201 were analysed (106 males), all undergoing a contrast-
enhanced abdominal CT with iopamidol (370 mgI/mL) or iomeprol (400 mgI/mL). LBW was estimated using
validated formulas. Liver contrast-enhancement (CEL) was measured. Data were reported as mean ± standard
deviation. Pearson correlation coefficient, ANOVA, and the Levene test were used.
Results: Mean age was 66 ± 13 years, TBW 72 ± 15 kg, LBW 53 ± 11 kg, and LBW/TBW ratio 74 ± 8%; body mass
index was 26 ± 5 kg/m2, with 9 underweight patients (4%), 82 normal weight (41%), 76 overweight (38%), and 34
obese (17%). The administered CA dose was 0.46 ± 0.06 gI/kg of TBW, corresponding to 0.63 ± 0.09 gI/kg of LBW. A
negative correlation was found between TBW and CA dose (r = -0.683, p < 0.001). CEL (Hounsfield units) was 51 ± 18
in underweight patients, 44 ± 8 in normal weight, 42 ± 9 in overweight, and 40 ± 6 in obese, with a significant
difference for both mean (p = 0.004) and variance (p < 0.001). A low but significant positive correlation was found
between CEL and CA dose in gI per TBW (r = 0.371, p < 0.001) or per LBW (r = 0.333, p < 0.001).
Conclusions: The injected CA dose was highly variable, with obese patients receiving a lower dose than
underweight patients, as a radiologist-driven ‘compensation effect’. Diagnostic abdomen CT examinations may be
obtained using 0.63 gI/kg of LBW.
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Key points
 Contrast agent dose based on total body weight
ignores body composition
 Underweight patients received a higher dose than
obese patients
 Diagnostic abdominal CT examinations may be
obtained using 0.63 gI/kg of lean body weight
Background
Factors impacting on contrast enhancement in
single-energy computed tomography (CT) include con-
centration and dose of the iodinated contrast agent (CA),
injection rate, scanning delay time, saline-solution flush-
ing, and cardiac output [1–3]. The CA dose, expressed in
gI/kg, is one of the most important factors determining
the parenchymal liver contrast enhancement (CEL) [4].
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When considering delayed scanning phases, another im-
portant factor determining CEL is the CA biodistribution
into the intra- and extra-vascular spaces, which are both
related to the body size [5, 6]. As a consequence, if a fixed
amount of iodine is administered to patients, which is still
a usual practice [7], some may receive an unnecessary
high dose while others may receive a suboptimal dose.
Since 2000, several studies have demonstrated smaller
variations in CEL when CA is dosed on the patient total
body weight (TBW) instead of administering a fixed
amount [8–14]. Dosing according to TBW is reasonably
effective, but it can lead to overdosing obese patients or
underdosing patients with high contribution of the lean
body weight (LBW) over the TBW, such as athletes. In-
deed, a large proportion of TBW of obese patients con-
sists of poorly perfused adipose tissue, where the CA
poorly distributes [2, 10, 15, 16], as 99% of metabolic
processes take place in the LBW [17, 18].
Various body size indexes have been proposed to de-
termine the CA dose for abdominal multiphasic or
portal-venous-phase CT, demonstrating better results
for LBW rather than TBW [16, 19–27]. LBW can be
determined by many different methods such as
dual-energy x-ray absorptiometry, CT, ultrasound, and
bioelectrical impedance analysis [28], although an equa-
tion based on the patient TBW, height, and gender, or
the determination by bioelectrical impedance balance is
the most suitable for calculation [18].
Previous studies using LBW for CA dose calculation
mainly compared different strategies and, to our know-
ledge, no study has performed an optimisation process
to find out what is the minimal diagnostic CA dose
based on the LBW [19–27]. Moreover, authors limited
their studies mainly to normal-weight or overweight
populations. In our opinion, advantages of CA dose cal-
culation based on the LBW instead of the TBW may ap-
pear mostly in underweight and obese patients.
The aim of this preliminary retrospective study was to
report on our experience on multiphasic abdominal CT
and to calculate the LBW-derived CA dose that was
equivalent to that derived from TBW, leading to the
same amount of injected iodine. In other words, our
final aim was to find a feasible formula to standardise
the amount of CEL across patients of all sizes, whereas
the amount of iodine delivered will vary by patient size
and by whether LBW or TBW is used to determine the
total amount of injected iodine.
Methods
Study design and population
This retrospective cross-sectional study was approved by
the local Ethics Committee (San Raffaele Hospital, Milan,
authorisation number 160/int/2016). A series of consecu-
tive patients who underwent a contrast-enhanced
multiphasic abdominal CT or portal-venous-phase CT at
our institution from June to September 2016 were
reviewed.
Exclusion criteria were: history of chronic liver disease
(cirrhosis, local or diffuse liver fatty infiltration, or glyco-
gen storage disease); congestive heart failure; prior car-
diac valve replacement; restrictive and/or constrictive
pericarditis; implanted devices (pacemakers, defibrilla-
tors, insulin pumps). Although Hamer et al. [29] defined
steatotic hepatitis when liver parenchyma has an average
CT value on unenhanced images lower than 40 Houns-
field units (HU), we excluded patients with CT values
below 30 HU in the unenhanced scan. As a conse-
quence, low grades of steatosis have presumably been in-
cluded in our study population.
CT protocol
All patients were studied using a 64-row CT scan
(Somatom Definition, Siemens Medical Solution,
Erlangen, Germany) with 120 kVp, tube load from 100
to 200 mAs depending on automatic exposure control
system (CARE Dose 4D, Siemens Medical Solution,
Erlangen, Germany), rotation time 0.5 s, pitch 1, B30f
medium smooth for kernel reconstruction technique
and abdomen window.
Patients’ TBW and height were registered in an elec-
tronic database. Moreover, a radiologist-driven dose of
iopamidol (190 patients over 201) (Iopamiro 370; 370
mgI/mL; Bracco Imaging, Milan, Italy) or iomeprol (11
patients over 201) (Iomeron 400; 400 mgI/mL; Bracco
Imaging, Milan, Italy) was administered. While iopami-
dol is the main choice in our hospital for routine abdo-
men and chest CT, iomeprol is used for cardiac CT. Due
to practical reasons (storage lack of iopamidol, the ne-
cessity of employing an already-open CA bottle, examin-
ation acquired during a cardiac session), some patients
received iomeprol. A total of eight radiologists were re-
sponsible for the examinations. The general rule estab-
lished in the department for the CA dose to be
administered for multiphasic abdominal CT was to use
doses proportional to the TBW, multiplying the patient
body weight by a constant, which varied from 1.1 to
1.3 mL/kg, with adjustments when the CA dose was
considered too high. Radiologists usually adopted their
own spontaneous threshold, without any agreement
among them. Another heuristic rule used by some pro-
fessionals was ‘patient weight in millilitres plus 10 add-
itional millilitres of CA’.
The CA was administered intravenously through a
20-gauge needle using an automatic power injector
(EmpowerCTA® Contrast Injection System, Bracco Im-
aging, Milan, Italy) at the rate of 3 mL/s, followed by
50 mL of saline solution at the same rate.
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The scan delay was determined using an automated trig-
gering hardware and a dedicated software (Bolus Tracking,
Siemens Medical Solution, Erlangen, Germany). Specific-
ally, low-dose monitor images were obtained in a single
axial slice of the aorta after CA injection. When the de-
scending aorta enhanced more than 100 HU, diagnostic
scans of the abdomen were acquired after an additional
delay of about 18 s (arterial phase), 30 s after arterial phase
(portal-venous phase), and, only in specific cases, 90 s
(nephrogenic phase). For the aim of this study, we consid-
ered only the portal venous phase.
LBW estimation and image analysis
According to the international classification of body
mass index (BMI) from the WHO [30], patients were
considered underweight when the BMI was lower than
18.5 kg/m2, normal weight when between 18.5 kg/m2
and 25 kg/m2, overweight when between 25 kg/m2 and
30 kg/m2, and obese when higher than 30 kg/m2.
According to Awai and colleagues [31] and Nyman
[32], LBW was calculated using the James formula [33]
(Eq. 1) or the Boer formula [33] (Eq. 2), due to better ad-
herence of non-obese patients to the first and of obese
patients to the latter:
LBWJames ¼
1:1 weight kgð Þ−128 weight kgð Þ
height mð Þ
 2
men
1:07 weight kgð Þ−148 weight kgð Þ
height mð Þ
 2
women
8>><
>>:
9>>=
>>;
ð1Þ
LBWBoer ¼ 0:407 weight kgð Þ þ 0:267 height−19:2 men0:252 weight kgð Þ þ 0:473 height−48:3 women
 
ð2Þ
All images were reviewed by a radiology resident with
2 years of experience in the field of abdominal CT. At-
tenuation measurements were obtained by manually pla-
cing a rounded region of interest in the anterior (III or
IVb Couinaud) and in the posterior (VI Couinaud) seg-
ments at the level of the main portal vein with a diam-
eter of between 2 and 3 cm; these two values were
averaged. Two different regions in anterior and posterior
liver parenchyma were chosen because of subtle territor-
ial differences in liver enhancement, probably due to dif-
ferent levels of fatty infiltration and vascularity. Focal
hepatic lesions, blood vessels, bile ducts, calcifications,
as well as artefacts, if present, were carefully avoided.
Statistical analysis
For each patient, we retrieved from the radiological re-
port the amount and type of injected CA in millilitres
and the dose was calculated both per TBW and LBW.
Moreover, to account for the different concentration of
iodine of the two used CAs, we converted the absolute
injected amount from millilitres to grams of iodine (gI).
The CEL was calculated as the difference between the
CT value measured in the portal venous phase and that
measured before CA injection. To this aim, regions of
interest were copy-pasted from one phase to another.
The distribution of CEL was calculated for the whole
population and for the four subgroups of BMI. Bivariate
correlation analysis was performed using the Pearson
correlation coefficient. The comparison of the mean CA
dose, as well as of the mean CEL among the four sub-
groups of BMI was performed using the one-way ana-
lysis of variance (ANOVA); the variance of CEL was
compared using the Levene test of homoscedasticity.
Differences in the practice of CA dose calculation
among radiologists were evaluated using the ANOVA.
Continuous data were presented as mean and standard
deviation while categorical data were presented as counts
and percentages. The coefficient of variation (CoV) was
calculated as the standard deviation/mean ratio.
Statistical analysis was carried out using SPSS Statistics
(SPSS v.24, IBM Inc., Armonk, NY, USA). A p value <
0.050 was regarded as statistically significant.
Results
Distributions
A total of 219 patients were screened, 18 of whom were ex-
cluded for having chronic liver disease (n = 13), implanted
device (n = 4), or congestive heart failure (n = 1). Thus, 201
patients were analysed, 106 men (53%) and 95 women
(47%), with a mean age of 66 ± 13 years (CoV 20%), mean
TBW 72 ± 15 kg (CoV 21%), mean LBW 53 ± 11 kg (CoV
20%), and mean LBW/TBW 74 ± 8% (CoV 11%).
The mean BMI was 26 ± 5 kg/m2 with 9 patients (4%)
classified as underweight, 82 (41%) as normal weight, 76
(38%) as overweight and 34 (17%) as obese. Demograph-
ics and other data of the study population are presented
in Table 1.
The mean injected amount of CA was 32 ± 5 gI (CoV
16%). Expressed in terms of gI/kg of TBW or LBW, the
mean CA dose was 0.46 ± 0.06 (CoV 13%) or 0.63 ± 0.09
(CoV 14%), respectively.
The mean CT value of the liver was 53 ± 8 HU before
CA injection and 96 ± 13 HU in the portal venous phase,
for a mean CEL of 43 ± 9 HU (CoV 21%). These and
other data are reported in Table 2.
Correlation analysis
A significant high negative correlation was observed be-
tween CA dose and TBW (r = -0.683; p < 0.001). In par-
ticular, the mean CA dose was 0.56 ± 0.08 gI/kg for
underweight, 0.48 ± 0.05 gI/kg for normal-weight pa-
tients, 0.44 ± 0.04 gI/kg for overweight patients, and
0.41 ± 0.05 gI/kg for obese patients (p < 0.001) (Fig. 1).
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A low but significant negative correlation was found
between CEL and TBW (r = -0.292; p < 0.001) or LBW
(r = -0.316; p < 0.001). A low but significant positive
correlation was found between CEL and CA dose in
gI/kg of TBW (r = 0.371, p < 0.001) or in gI/kg of
LBW (r = 0.333, p < 0.001).
A low but significant negative correlation was found
between CEL and BMI (r = -0.206; p = 0.003). According
to the four subgroups of BMI, the mean CEL was 51 ±
18 HU (CoV 35%) in underweight patients, 44 ± 8 HU
(CoV 18%) in normal-weight patients, 42 ± 9 HU (CoV
18%) in overweight patients, and 40 ± 6 HU (CoV 15%)
in obese patients with a statistically significant difference
of both the mean (p = 0.004) and variance (p < 0.001).
The mean CA dose in gI/kg of TBW did not differ sig-
nificantly among the eight radiologists, varying from
0.43 to 0.47 gI/kg (p = 0.510).
Discussion
In this study, we retrospectively evaluated 201 patients
undergoing an abdominal CT at our institution. The
main finding was the evidence of a kind of ‘compensa-
tion effect’, subjectively operated by the radiologists, on
the injected CA dose, always considering its calculation
in terms of gI/kg. In fact, we observed a deviation from
proportionality between the TBW and the injected CA
dose that they declared when questioned about how they
decide CA dose. This was clear in particular for obese
patients, which received a CA dose lower than that the-
oretically based on the TBW. Indeed, a high negative
correlation was found between the patient TBW and the
administered CA dose, meaning that the higher the
TBW, the lower the CA dose.
Although there are no recommendations for obese pa-
tients (apart from a general limit of 250 mL reported on the
drug information sheet), radiologists preferred to apply a
kind of precautionary principle by subjectively reducing CA
dose in obese patients. We could speculate that radiologists
have somehow weighted the CA dose according to a plaus-
ible LBW, even without being aware of the exact LBW.
Importantly, although the CA dose was reduced in
obese patients, all CT examinations were judged as diag-
nostic and no patients received a repeat examination. This
allows us to hypothesise a margin for dose reduction,
especially in underweight patients, who in our study
received a dose in gI/kg significantly higher than obese
ones. In fact, the other side of the above-mentioned com-
pensation effect is a potential overdosing in underweight
patients, partially due to the fear of a non-diagnostic
examination if injected strictly according to the TBW.
Another result of this study is a trend toward a lower
and lower variability of CEL from underweight to obese
patients (Levene test p < 0.001). We speculate that this
evidence indirectly demonstrates that LBW could be
Table 1 Demographic characteristics of 201 patients of the
study population
Item Value
Total number of patients 201
Gender 106 males (53%)
Mean age (years) 66 ± 13
Mean height (m) 1.66 ± 0.10
Mean TBW (kg) 72 ± 15
Mean LBW (kg) 53 ± 11
Mean percent LBW/TBW (%) 74 ± 8
Mean BMI (kg/m2): 26 ± 5
Underweight (BMI < 18.5 kg/m2) 9 (4%)
Normal weight (18.5≤ BMI < 25 kg/m2) 82 (41%)
Overweight (25 ≤ BMI < 30 kg/m2) 76 (38%)
Obese (BMI≥ 30 kg/m2) 34 (17%)
BMI body mass index, LBW lean bodyweight, TBW total bodyweight
Table 2 Mean contrast agent dose administered in 201 patients
of the study population
Item Valuea CoV
Amount of injected CA (g) 32 ± 5 16%
Dose of CA per TBW (gI/kg) 0.46 ± 0.06 13%
Dose of CA per TBW (gI/kg) according to BMIb
Underweight (BMI < 18.5 kg/m2) 0.56 ± 0.08 14%
Normal weight (18.5≤ BMI < 25 kg/m2) 0.48 ± 0.05 10%
Overweight (25 ≤ BMI < 30 kg/m2) 0.44 ± 0.04 9%
Obese (BMI≥ 30 kg/m2) 0.41 ± 0.04 10%
Dose of CA per LBW (gI/kg) 0.63 ± 0.09 14%
Dose of CA per LBW (gI/kg) according to BMIc
Underweight (BMI < 18.5 kg/m2) 0.68 ± 0.11 16%
Normal weight (18.5≤ BMI < 25 kg/m2) 0.62 ± 0.08 13%
Overweight (25 ≤ BMI < 30 kg/m2) 0.62 ± 0.08 13%
Obese (BMI≥ 30 kg/m2) 0.65 ± 0.11 17%
Liver contrast enhancement (HU)d 43 ± 9 21%
Liver contrast enhancement (HU) according to BMIe
Underweight (BMI < 18.5 kg/m2) 51 ± 18 35%
Normal weight (18.5≤ BMI < 25 kg/m2) 44 ± 8 18%
Overweight (25 ≤ BMI < 30 kg/m2) 42 ± 9 18%
Obese (BMI≥ 30 kg/m2) 40 ± 6 15%
aData represent mean ± standard deviation
bThis trend showed a significant negative association (p < 0.001)
cThe comparison was not statistically significant (p ≥ 0.065)
dCalculated as the difference between the computed tomography (CT) value
measured in the venous phase and that measured before contrast
agent injection
eThis trend showed a significant negative association (p = 0.004)
BMI body mass index, CA contrast agent, CoV coefficient of variation, gI grams
of iodine, HU Hounsfield units, LBW lean bodyweight, TBW total bodyweight
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better suited for dosing CA than TBW. In fact, poor but
non-negligible CA perfusion in the adipose tissue would
only increase variability of CEL.
Interestingly, the practice of adjusting the CA dose, un-
consciously weighting for the LBW, was observed in all
the staff radiologists, without significant differences
among them. Of note, this shared practice spontaneously
evolved in the department real-life. In addition, repeat CT
examinations due to insufficient parenchymal contrast-en-
hancement has never been reported.
We also obtained an equivalent CA dose, i.e. the CA
dose based on the LBW that would have provided the
same amount of iodine that was actually administered.
In the study population, a mean of 32 ± 5 gI was
injected, corresponding to 0.46 ± 0.06 gI/kg of TBW or
0.63 ± 0.09 gI/kg of LBW. Although the latter data were
back calculated from the raw data, it is reasonably to
think that if 0.63 gI/kg of LBW had been used instead of
0.46 gI/kg of TBW, it would have resulted in an equiva-
lent mean CEL.
The use of LBW instead of TBW on a patient-by-patient
base could impact on the overall CA dose to the popula-
tion, permitting a more personalised approach to CA ad-
ministration and a possible reduction of the total amount
of CA administered to the population. Moreover, as obes-
ity increases the risk for kidney disease [34], a reduction of
the overall dose to obese patients represents a further ad-
vantage in terms of risk of nephrotoxic effects from iodin-
ated CA. The associated cost reduction, dependent on
changes in administered volume, is another advantage po-
tentially deriving from this approach [7]. However, al-
though Awai et al. [31] have already identified LBW as the
best indicator for determining the proper amount of CA,
its use has never entered clinical practice.
When optimising CA dose, several factors should be
taken into account [35]. From pharmacokinetics, it is
known that drug distribution in the arterial phase mainly
depends on heart function, while in the portal venous
phase vasoconstriction-vasodilatation play the main role
in determining CA distribution [18, 36]. We based our
Fig. 1 Box plot showing the mean CA dose (in grams of iodine per kilogram of total body weight) per each of the 4 subgroups of the body
mass index (BMI) according the WHO (centre line). Mean ± standard deviation (box) and the minimum and the maximum values are also showed
(outer lines)
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results on CEL but a wide variety of para-physiological
conditions can affect liver parenchyma in the general
population (e.g. steatotic hepatitis, diffuse cirrhosis, pre-
vious liver diseases) that can affect CEL.
This study has limitations. First of all, its retrospective
design and relatively small number of patients, which
implies an uneven distribution of patient weights. In
addition, we estimated the patient LBW using the James
or Boer formulas. Indeed, LBW determined with the aid
of a total body composition analyser may yield a more
accurate analysis. There are several prediction formulas
for LBW [33, 37–39] that may yield different results.
However, for the aim of our study, the formulas we used
are considered the simplest methods for retrospective
calculation of the LBW, confirmed by Caruso et al. [40].
In conclusion, the CA dose injected at our institu-
tion for abdominal multiphasic CT was highly vari-
able, with obese patients receiving a much lower dose
than underweight patients, as a radiologist-driven
‘compensation effect’. Diagnostic abdominal CT may
be obtained using 0.63 gI/kg of LBW and margins for
dose reduction do exist.
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